Tachycardia induced cardiomyopathy

Jump to navigation Jump to search

Cardiomyopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cardiomyopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Guidelines

2023 ESC Guideline Recommendations

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy

Case Studies

Case #1

Tachycardia induced cardiomyopathy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tachycardia induced cardiomyopathy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tachycardia induced cardiomyopathy

CDC on Tachycardia induced cardiomyopathy

Tachycardia induced cardiomyopathy in the news

Blogs on Tachycardia induced cardiomyopathy

Directions to Hospitals Treating Cardiomyopathy

Risk calculators and risk factors for Tachycardia induced cardiomyopathy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and Keywords: chronotropic cardiomyopathy, tachycardiomyopathy

Overview

Tachycardia induced cardiomyopathy is a decline in left ventricular function and left ventricular dilation as a result of chronic or frequently recurring paroxysmal tachycardia. The tachycardia can either be an atrial tachycardia or a ventricular tachycarrhythmia. Depending upon the duration of the tachycardia, the condition is either completely or partially reversible.

Historical Perspective

The relationship between tachycardia and a reversible decline in left ventricular dysfunction was first described by Phillips and Levine in 1949 [1].

Pathophysiology

Animal models demonstrate that sustained atrial or ventricular pacing results in dilation of all four cardiac chambers with thinning of the left and right ventricular walls. Both diastolic and systolic dysfunction develops in all four chambers as well.

Risk Factors

The rate and duration of the elevation in heart rate necessary to cause a cardiomyopathy is unclear and is likely dependent on a number of unknown factors.

Prognosis

Depending upon the duration of the tachycardia, the condition is either completely or partially reversible.

Treatment

The primary treatment for a tachycardia induced cardiomyopathy is correct the underlying tachycardia. Supportive agents such as beta blockers and ACE inhibitors / angiotensin receptor blockers are of benefit to try to prevent remodeling of the left ventricle.

Not only is there a need to control the tachycardia that is responsible for causing tachycardia induced cardiomyopathy, but also treating underlying conditions that cause tachycardia. For instance, treatment of hyperthyroidism can also lead to reversal of tachycardia induced cardiomyopathy.

References

  1. Phillips E, Levine SA. Auricular fibrillation without other evidence of heart disease: a cause of reversible heart failure. Am J Med 1949; 7:478-89.


Template:WikiDoc Sources